Mouse anti-Human, Mouse MET Monoclonal Antibody | anti-MET antibody

MET (HGF Receptor, HGFR, Hepatocyte Growth Factor Receptor, Scatter Factor Receptor, SF Receptor, HGF/SF Receptor, Tyrosine-Protein Kinase Met, Proto-Oncogene c-Met) (Azide free) (HRP)

Cat. Num. AAA6121542

• Gene Names: MET; HGFR; AUTS9; RCCP2; c-Met
• Reactivity: Human, Mouse
• Applications: ELISA, Immunohistochemistry, Western Blot
• Purity: Purified by Protein G Affinity Chromatography
• Synonyms: MET; Monoclonal Antibody; MET (HGF Receptor; HGFR; Hepatocyte Growth Factor Receptor; Scatter Factor Receptor; SF Receptor; HGF/SF Receptor; Tyrosine-Protein Kinase Met; Proto-Oncogene c-Met) (Azide free) (HRP); anti-MET antibody

• Host: Mouse
• Reactivity: Human, Mouse
• Clonality: Monoclonal
• Isotype: IgG1
• Clone Number: 10i55
• Specificity: Recognizes human HGF receptor. Species Crossreactivity: mouse.
• Purity/Purification: Purified by Protein G Affinity Chromatography
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with horseradish peroxidase (HRP).

• Applicable Applications for anti-MET antibody: ELISA (EIA), Immunohistochemistry (IHC), Western Blot (WB)
• Application Notes: ELISA: 1:1000; IHC: 1:50-1:100; WB: 1:100-1:500; Applications are based on unconjugated antibody.
• Immunogen: Purified recombinant protein encoding the catalytic domain of human Met.
• Conjugate: HRP
• Preparation and Storage: Store product at 4 degree C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20 degree C. Aliquots are stable at -20 degree C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Immunofluorescence (IF)

(Fluorescent confocal image of HepG2 cells stained with MET/HGFR antibody. HepG2 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AM1003a MET/HGFR primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-mouse antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 μg/ml, 5 min). Note the highly specific localization of the MET immunosignal to the cytoplasm, supported by Human Protein Atlas Data.)

Immunohistochemistry (IHC)

(MET/HGFR Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human hepatocarcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of the MET/HGFR Antibody for immunohistochemistry. Clinical relevance has not been evaluated.)

Testing Data

(Detection of endogenous Met in HepG2 cell line. 10 ug/lane of HepG2 cell lysate was used to examine the expression of human Met. Lanes 1-5 represent different anti-Met monoclonal antibodies. Lane 6 represents auto-phosohorylated-Met in HepG2 cell line detected by anti-phospho-Met Mab.)

Product Categories/Family for anti-MET antibody

Antibodies; Growth Factors; Cytokines

References

1. Furge, K.A., et al., Oncogene 19(49): 5582-5589 (2000). 2. Dean, M., et al., Nature 318(6044): 385-388 (1985). 3. Dean, M., et al., Mol. Cell. Biol. 7(2): 921-924 (1987). 4. Park, M., et al., Proc. Natl. Acad. Sci. USA 84(18): 6379-6383 (1987). 5. Bottaro, D.P., et al., Science 251(4995): 802-804 (1991).

NCBI and Uniprot Product Information

• NCBI GI #: 42741655
• NCBI GeneID: 4233
• NCBI Accession #: NP_000236.2
• NCBI GenBank Nucleotide #: NM_000245.2
• UniProt Accession #: P08581; O60366; Q12875; Q9UDX7; Q9UPL8; A1L467; B5A932; E7EQ94
• Molecular Weight: 155,541 Da
• NCBI Official Full Name: hepatocyte growth factor receptor isoform b
• NCBI Official Synonym Full Names: met proto-oncogene (hepatocyte growth factor receptor)
• NCBI Official Symbol: MET
• NCBI Official Synonym Symbols: HGFR; AUTS9; RCCP2; c-Met
• NCBI Protein Information: hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase
• UniProt Protein Name: Hepatocyte growth factor receptor
• Protein Family: Metaxin
• UniProt Gene Name: MET
• UniProt Synonym Gene Names: HGF receptor; SF receptor
• UniProt Entry Name: MET_HUMAN

NCBI Description

The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

Function: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. Ref.14 Ref.17 Ref.25Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells. Ref.14 Ref.17 Ref.25

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

Enzyme regulation: In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.

Subunit structure: Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4

By similarity. Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. Interacts with MUC20; prevents interaction with GRB2 and suppresses hepatocyte growth factor-induced cell proliferation. Interacts with GRB10. Ref.12 Ref.16 Ref.18 Ref.19 Ref.20 Ref.22 Ref.24 Ref.25 Ref.26 Ref.34 Ref.48

Subcellular location: Membrane; Single-pass type I membrane protein. Isoform 3: Secreted.

Tissue specificity: Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain. Ref.11 Ref.13

Domain: The kinase domain is involved in SPSB1 binding.The beta-propeller Sema domain mediates binding to HGF.

Post-translational modification: Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Ref.15 Ref.16 Ref.23 Ref.26Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Ref.15 Ref.16 Ref.23 Ref.26Ubiquitinated. Ubiquitination by CBL regulates the receptor stability and activity through proteasomal degradation. Ref.21

Involvement in disease: Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.Defects in MET may be associated with gastric cancer.Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.43Renal cell carcinoma papillary (RCCP) [MIM:605074]: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.41 Ref.42 Ref.44 Ref.45A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies. Ref.51

Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family.Contains 3 IPT/TIG domains.Contains 1 protein kinase domain.Contains 1 Sema domain.